Jun 08, 2020
Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial Device
Feb 04, 2020
Nuvaira Announces Chief Financial Officer and Pivotal Study Milestone
Jan 30, 2020
Pulmatrix Receives Fast Track Designation for Pulmazole for the Treatment of Asthma-ABPA
Dec 18, 2019
Additional Patients Eligible for New COPD Treatment with Expansion of UnitedHealthcare® Coverage
Nov 04, 2019
Pulmatrix appoints Life Sciences Executive Rick Batycky to the Board of Directors
Oct 14, 2019
Identification of COPD, asthma and overlap syndrome can be teased out with spirometry following use of bronchodilator
Aug 19, 2019
Nuvaira Announces Peer-Reviewed Publications of Targeted Lung Denervation Mechanisms of Action and Clinical Outcomes
Aug 01, 2019
Olympus SVS Endobronchial Valve Clinical Trial Results Published in "Blue Journal," The American Journal of Respiratory and Critical Care Medicine
Jul 09, 2019
Pulmatrix Activates Sites for Pulmazole Phase 2 Clinical Study
Jun 10, 2019
First patients successfully treated in the Nuvaira AIRFLOW-3 COPD pivotal trial
May 09, 2019
Ally Bridge Group Leads Pulmonx's $65 Million Financing, Further Strengthening Its Global Medtech Franchise
May 02, 2019
Nuvaira Receives French Innovation Funding for AIRFLOW-3 Pivotal Trial
Mar 29, 2019
First Patient Treated for Severe Emphysema with the FDA-Approved Spiration® Valve System
Jan 22, 2019
Olympus Launches Spiration® Valve System for the Endobronchial Treatment of Severe Emphysema
Nov 15, 2018
Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology
Oct 18, 2018
Lung Health Institute Presents New Findings at 7th Annual International Symposium on Regenerative Rehabilitation
Oct 11, 2018
Theravance Biopharma and Mylan Report Positive New Data from Multiple Studies of YUPELRI(TM) (revefenacin) at the 2018 CHEST Annual Meeting
Oct 08, 2018
Theravance Biopharma and Mylan to Present New Data from Studies of YUPELRI(TM) (revefenacin) at the 2018 CHEST Annual Meeting
Sep 17, 2018
Pulmatrix to present pre-clinical data on PUR1800 (RV1162) at the European Respiratory Society International Congress
Sep 04, 2018
Natural "Breakdown" of Chemicals Predicts Lung Damage in 9/11 Firefighters